Rexer H
Urologe A. 2005 Apr;44(4):408-11. doi: 10.1007/s00120-005-0795-7.
With more than 85,000 newly diagnosed cancers per year, uro-oncology alone represents a significant part in the field of oncology in Germany. Therefore, the Task Group for Uro-Oncology (The Association of Urogenital Oncology, AUO) of the German Cancer Association (DKG) was founded in 1989 to enforce high quality in research on urological cancer. The main aim has been to improve the quality of clinical cancer studies. The board of the AUO reviews, certifies and gives accreditation to study protocols with respect to GCP standards, likelihood of realisation and scientific impact of the study objectives. To support enrolment of patients, the AUO initiated a study group of more than 85 clinical centers of excellence and publishes timely details on the different studies in the appropriate media. Moreover, the members of the AUO board organize seminars, scientific meetings and pharmaceutical hearings. In this article, the organisation's structure is described in detail. Various aspects of AUO work, carried out over the years, are highlighted, and data presented on the outcome of studies.
德国每年有超过85000例新发癌症病例，仅尿路上皮肿瘤学就在德国肿瘤学领域占据重要地位。因此，德国癌症协会（DKG）的尿路上皮肿瘤学工作组（泌尿生殖系统肿瘤协会，AUO）于1989年成立，以确保泌尿生殖系统癌症研究的高质量。其主要目标是提高临床癌症研究的质量。AUO董事会根据GCP标准、研究实现的可能性以及研究目标的科学影响，对研究方案进行审查、认证并给予认可。为了支持患者入组，AUO发起了一个由85多个卓越临床中心组成的研究小组，并在适当的媒体上及时公布不同研究的详细信息。此外，AUO董事会成员组织研讨会、科学会议和药物听证会。本文详细描述了该组织的结构。重点介绍了多年来AUO工作的各个方面，并展示了研究结果的数据。
